GlaxoSmithKline Pharmaceuticals Limited received a tax refund of ₹52.00 crore for Assessment Year 1984-85 on August 6, 2026, following a final order from the Commissioner of Income Tax (Appeals). The resolution of this decades-old assessment resulted in additional interest income of ₹42.09 crore, which the company has credited to its profit and loss account. This inflow represents a significant non-operational boost to the company’s financials, closing a prolonged dispute with tax authorities.

The disclosure was made under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. GlaxoSmithKline informed the Bombay Stock Exchange and the National Stock Exchange of India Limited regarding the receipt of the Order Giving Effect (OGE) to the CIT-Appeal. The OGE was issued on January 27, 2026, but the actual funds were credited to the company’s bank account on August 6, 2026.

Key Details of the Refund

The tax authority involved was the ACIT Cir 7(1)(1), which had previously determined a demand liability of ₹23.21 crores. However, the final appellate order reversed this position, leading to the substantial refund. There were no violations or contraventions alleged by the authority in the final communication.

Financial Impact

The primary material impact of this event is the recognition of ₹42.09 crore as interest income. This amount is distinct from the principal refund of ₹52.00 crore. The interest accrued over the extended period between the original assessment year and the final settlement. By crediting this to the profit and loss account, GlaxoSmithKline will see a direct positive impact on its net profit for the period in which the refund was received.

What the Numbers Show

The magnitude of the interest income relative to the principal refund highlights the duration of the dispute. With interest totaling ₹42.09 crore on a principal of ₹52.00 crore, the cost of capital for the tax authority over the intervening years was significant. For investors, this is a one-time, non-recurring gain that improves bottom-line metrics but does not reflect operational performance. The closure of the AY 1984-85 assessment also eliminates any future contingent liability or uncertainty associated with this specific fiscal year.

GlaxoSmithKline Pharmaceuticals Limited has uploaded audio recordings of its recent analyst and institutional investor meetings to its official website. The disclosure, made on August 5, 2026, ensures transparency for shareholders and market participants regarding management interactions with financial intermediaries.

The company filed the disclosure with BSE Limited and The National Stock Exchange of India Limited pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulatory requirement mandates listed entities to make available the recordings of such meetings to prevent information asymmetry between institutional and retail investors.

Compliance Details

The audio files are accessible via the company’s investor relations portal at india-pharma.gsk.com/en-in/investors/analyst-meets/. The filing was signed by Ajay Nadkarni, Vice President – Administration, Real Estate & Company Secretary. The digital signature confirms the submission date and time as August 5, 2026, at 14:59:11 IST.

This routine disclosure underscores GSK’s adherence to corporate governance standards set by the Securities and Exchange Board of India. By making these recordings public, the company allows all stakeholders to review the context and content of discussions held with analysts and institutional investors during the specified period.